Logo

PharmaShots Weekly Snapshots (December 13 - 17, 2021)

Share this

PharmaShots Weekly Snapshots (December 13 - 17, 2021)

Ipsen Signs an Exclusive License Agreement with GENFIT for Elafibranor to Treat Primary Biliary Cholangitis

Published: Dec 17, 2021 | Tags: Ipsen, GENFIT, Elafibranor, Primary Biliary Cholangitis

Merck and Ridgeback Publishes the Results of Molnupiravir in the P-III (MOVe-OUT) Trial for the Treatment of COVID-19 in the NEJM

Published: Dec 17, 2021 | Tags: Merck, Ridgeback, Molnupiravir, P-III, MOVe-OUT Trial, COVID-19, NEJM

BioMarin Collaborates with Skyline to Develop and Commercialize AAV Gene Therapies for Genetic Cardiovascular Diseases

Published: Dec 17, 2021 | Tags: BioMarin, Skyline, Gene Therapies, Cardiovascular Diseases

Daiichi Sankyo and Kite’s Yescarta (Axicabtagene Ciloleucel) CAR T-Cell Therapy Receives MHRA’s Approval for the Treatment of Lymphoma in Japan

Published: Dec 17, 2021 | Tags: Daiichi Sankyo, Kite, Yescarta, Axicabtagene Ciloleucel, CAR T-Cell Therapy, MHRA, Approval, Lymphoma, Japan

Pfizer’s Paxlovid (nirmatrelvir and ritonavir) Receives CHMP's Recommendation for the Treatment of COVID-19

Published: Dec 17, 2021 | Tags: Pfizer, Paxlovid, nirmatrelvir, ritonavir, CHMP, COVID-19

Alpine Signs an Exclusive License and Collaboration Agreement with Horizon to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases

Published: Dec 17, 2021 | Tags: Alpine, Horizon, Protein-Based Therapies, Autoimmune, Inflammatory Diseases

Takeda Reports Submission of NDA to MHLW for Novavax’s NVX-CoV2373 to Treat COVID-19

Published: Dec 16, 2021 | Tags: Takeda, NDA, MHLW, Novavax, NVX-CoV2373, COVID-19

Apellis and Sobi’s Aspaveli (pegcetacoplan) Receives EC’s Approval for the Treatment of PNH

Published: Dec 16, 2021 | Tags: Apellis, Sobi, Aspaveli, pegcetacoplan, EC, Approval, PNH

BMS’s Orencia (abatacept) Receives the US FDA’s Approval for the Prevention of Acute Graft Versus Host Disease

Published: Dec 16, 2021 | Tags: BMS, Orencia, abatacept, US, FDA, Approval, Acute Graft Versus Host Disease

BioXcel Initiates P-III (TRANQUILITY) Program of BXCL501 for the Acute Treatment of Agitation in Patients with Alzheimer’s Disease

Published: Dec 16, 2021 | Tags: BioXcel, P-III, TRANQUILITY Program, BXCL501, Alzheimer’s Disease

Jazz Reports First Patient Enrollment in P-IIb Clinical Trial of Suvecaltamide for the Treatment of Essential Tremor

Published: Dec 16, 2021 | Tags: Jazz, P-IIb, Clinical Trial, Suvecaltamide, JZP385, Essential Tremor

Johnson & Johnson Receives CHMP's Positive Opinion of COVID-19 Booster Vaccine for the Treatment of COVID-19

Published: Dec 16, 2021 | Tags: Johnson & Johnson, CHMP, Positive Opinion, COVID-19 Booster Vaccine, COVID-19

Ichnos Signs an Exclusive License Agreement with Almirall for ISB 880 to Treat Autoimmune Diseases

Published: Dec 15, 2021 | Tags: Ichnos, Almirall, ISB 880, Autoimmune Diseases

Genentech Reports Results of Polivy (polatuzumab vedotin) in P-III (POLARIX) Study for the Treatment of Diffuse Large B-Cell Lymphoma

Published: Dec 15, 2021 | Tags: Genentech, Polivy, polatuzumab vedotin, P-III, POLARIX Study, Diffuse Large B-Cell Lymphoma

Eli Lilly Reports Results of Mirikizumab in P-III (LUCENT-2) Maintenance Study for the Treatment of Ulcerative Colitis

Published: Dec 15, 2021 | Tags: Eli Lilly, Mirikizumab, P-III, LUCENT-2, Maintenance Study, Ulcerative Colitis

Pfizer’s Xeljanz (tofacitinib) Receives US FDA’s Approval for the Treatment of Active Ankylosing Spondylitis

Published: Dec 15, 2021 | Tags: Pfizer, Xeljanz, tofacitinib, US, FDA, Approval, Active Ankylosing Spondylitis

CSL to Acquire Vifor Pharma for ~$11.7B

Published: Dec 15, 2021 | Tags: CSL, Acquire, Vifor Pharma, ~$11.7B

BMS Signs an Exclusive License Agreement with Immatics to Develop and Commercialize IMA401 for the Treatment of Cancer

Published: Dec 15, 2021 | Tags: BMS, Immatics, IMA401, Cancer

Junshi and Coherus Reports Interim Results of Toripalimab in P-III (CHOICE-01) Trial as 1L Treatment for Non-Small Cell Lung Cancer

Published: Dec 14, 2021 | Tags: Junshi, Coherus, Toripalimab, P-III, CHOICE-01 Trial, Non-Small Cell Lung Cancer

AstraZeneca Expands its Manufacturing Partnership with Samsung Biologics for AZD7442 to Treat COVID-19

Published: Dec 14, 2021 | Tags: AstraZeneca, Samsung Biologics, AZD7442, COVID-19

Janssen Presents Results of Teclistamab in (MajesTEC-1) Study for the Treatment of Multiple Myeloma at ASH 2021

Published: Dec 14, 2021 | Tags: Janssen, Teclistamab, MajesTEC-1 Study, Multiple Myeloma, ASH 2021

Arbutus Signs an Exclusive Licensing Agreement with Qilu to Develop and Commercialize AB-729 for the Treatment of Hepatitis B

Published: Dec 14, 2021 | Tags: Arbutus, Qilu, AB-729, Hepatitis B

Lilly Collaborates with Foghorn to Develop Novel Oncology Therapies for the Treatment of Cancer

Published: Dec 14, 2021 | Tags: Lilly, Foghorn, Novel Oncology Therapies, Cancer

Pfizer to Acquire Arena for ~ $6.7B

Published: Dec 14, 2021 | Tags: Pfizer, Acquire, Arena, ~ $6.7B

BMS Entered into a Clinical Collaboration with Antengene to Evaluate ATG-017 + Opdivo (nivolumab) for Advanced Solid Tumors

Published: Dec 13, 2021 | Tags: BMS, Antengene, ATG-017, Opdivo, nivolumab, Advanced Solid Tumors

Jazz and PharmaMar Initiates P-III (LAGOON) Trial of Zepzelca (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer

Published: Dec 13, 2021 | Tags: Jazz, PharmaMar, P-III, LAGOON Trial, Zepzelca, lurbinectedin, Small Cell Lung Cancer

AstraZeneca Presents Results of Calquence in the P-III (ASCEND) Trial for the Treatment of Chronic Lymphocytic Leukaemia at ASH 2021

Published: Dec 13, 2021 | Tags: AstraZeneca, Calquence, P-III, ASCEND, Trial, Chronic Lymphocytic Leukaemia, ASH 2021

Sanofi Presents Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Atopic Dermatitis at RAD 2021

Published: Dec 13, 2021 | Tags: Sanofi, Dupixent, dupilumab, P-III, Trial, Atopic Dermatitis, RAD 2021

AbbVie Entered into a Clinical Trial Collaboration Agreement with SpringWorks to Evaluate ABBV-383 + Nirogacestat for Multiple Myeloma

Published: Dec 13, 2021 | Tags: AbbVie SpringWorks, ABBV-383, Nirogacestat, Multiple Myeloma

Lilly Entered into a Multi-Year Research Collaboration with Regor to Discover, and Commercialize Novel Therapies for Metabolic Disorders

Published: Dec 13, 2021 | Tags: Lilly, Regor, Novel Therapies, Metabolic Disorders

Related Post: PharmaShots Weekly Snapshots (December 06-10, 2021)


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions